Medication induced blood pressure reduction; assessment of cerebral perfusion and cognition in hypertensive elderly

Medication induced blood pressure reduction; assessment of cerebral perfusion and cognition in hypertensive elderly - MBRACE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33986

Enrollment

Registered

2009-04-07

Start date

2009-08-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure hypertension

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Systolic hypertension grade II-III ( Systolic BP >=160mmHg) as measured according to JNC-7 protocol

Exclusion criteria

Exclusion criteria: •Systolic blood pressure >220mmHg •Indication for urgent treatment of HT •Contra-indication for MRI including claustrophobia •Contra-indication for anti-hypertensive medication used (Chlorthalidone, Amlodipine, Valsartan) •Dementia •Renal failure requiring dialysis •Atrial fibrillation •A life expectancy of less than a year •Disabling stroke •Impairment by any cause prohibiting participation as mentioned by the general practitioner •Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame
Total cerebral blood flow as measured by MRI. Difference between baseline measurement and end measurements after reaching systolic blood pressure target of 140mmHg.	—

Secondary

Measure	Time frame
1. Additional cerebral hemodynamics: a. Cerebral blood flow velocity in the middle cerebral artery as measured by transcranial Doppler sonography (TCD) b. Cerebral autoregulation c. Vasomotor reactivity 2. Cognition: Executive function, attention and memory as measured with CANTAB 3. The incidence of orthostatic hypotension 4. Blood pressure profile as measured by 24h ABPM a. Change in nocturnal dipping of BP b. Change in postprandial hypotension, in combination with food diary 5. Change in quality of life 6. Changes on structural MRI (white matter lesions, lacunar stroke, global and hippocampal atrophy) and functional MRI (fractional anisotropy (DTI), resting state connectivity, neurovascular coupling).	—

Measure

Time frame

1. Additional cerebral hemodynamics: a. Cerebral blood flow velocity in the middle cerebral artery as measured by transcranial Doppler sonography (TCD) b. Cerebral autoregulation c. Vasomotor reactivity 2. Cognition: Executive function, attention and memory as measured with CANTAB 3. The incidence of orthostatic hypotension 4. Blood pressure profile as measured by 24h ABPM a. Change in nocturnal dipping of BP b. Change in postprandial hypotension, in combination with food diary 5. Change in quality of life 6. Changes on structural MRI (white matter lesions, lacunar stroke, global and hippocampal atrophy) and functional MRI (fractional anisotropy (DTI), resting state connectivity, neurovascular coupling).

—

Countries

Netherlands

Outcome results